HK1136310A1 - Selective glucagon-like-peptide-2 (glp-2) analogues - Google Patents

Selective glucagon-like-peptide-2 (glp-2) analogues

Info

Publication number
HK1136310A1
HK1136310A1 HK10103774.4A HK10103774A HK1136310A1 HK 1136310 A1 HK1136310 A1 HK 1136310A1 HK 10103774 A HK10103774 A HK 10103774A HK 1136310 A1 HK1136310 A1 HK 1136310A1
Authority
HK
Hong Kong
Prior art keywords
glp
analogues
peptide
selective glucagon
glucagon
Prior art date
Application number
HK10103774.4A
Other languages
English (en)
Inventor
Bjarne Due Larsen
Yvette Miata Petersen
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of HK1136310A1 publication Critical patent/HK1136310A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Plant Pathology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
HK10103774.4A 2006-11-08 2010-04-20 Selective glucagon-like-peptide-2 (glp-2) analogues HK1136310A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200601456 2006-11-08
US85931306P 2006-11-15 2006-11-15
PCT/GB2007/004273 WO2008056155A1 (en) 2006-11-08 2007-11-08 Selective glucagon-like-peptide-2 (glp-2) analogues

Publications (1)

Publication Number Publication Date
HK1136310A1 true HK1136310A1 (en) 2010-06-25

Family

ID=41232246

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10103774.4A HK1136310A1 (en) 2006-11-08 2010-04-20 Selective glucagon-like-peptide-2 (glp-2) analogues

Country Status (15)

Country Link
US (2) US8642727B2 (de)
EP (1) EP2051995B1 (de)
JP (1) JP5819586B2 (de)
KR (1) KR101527233B1 (de)
CN (1) CN101573376B (de)
AU (1) AU2007319066B2 (de)
BR (1) BRPI0718566A2 (de)
CA (1) CA2669806C (de)
EA (1) EA023886B1 (de)
HK (1) HK1136310A1 (de)
IL (1) IL198127A (de)
MX (1) MX2009004701A (de)
NZ (2) NZ576260A (de)
UA (1) UA102506C2 (de)
WO (1) WO2008056155A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101200227B1 (ko) * 2005-05-04 2012-11-13 질랜드 파마 에이/에스 글루카곤 유사 펩티드-2(ｇｌｐ-2) 유사체
JP5819586B2 (ja) 2006-11-08 2015-11-24 ジーランド ファーマ アクティーゼルスカブ 選択的グルカゴン様ペプチド−２（ｇｌｐ−２）類似体
CN102942626B (zh) * 2009-03-05 2015-11-04 江苏豪森医药集团有限公司 胰高血糖素样肽-2类似物及其制备方法和用途
EP2311486A1 (de) * 2009-10-07 2011-04-20 Nestec S.A. GLP-2 zur Verwendung in der Dünndarm- und Muskelwiederherstellung
EP2314616A1 (de) * 2009-10-23 2011-04-27 Ferring B.V. GLP-2-Peptid-Agonisten
US9089538B2 (en) 2010-04-27 2015-07-28 Zealand Pharma A/S Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
CA2846680C (en) 2010-08-30 2019-06-25 Takeda Gmbh Solid phase synthesis of h[gly2]glp-2
JP6359972B2 (ja) 2011-11-03 2018-07-18 ジーランド ファーマ アクティーゼルスカブ Ｇｌｐ−１受容体アゴニストペプチドガストリンコンジュゲート
AU2013255752B2 (en) 2012-05-03 2017-11-09 Zealand Pharma A/S Glucagon-like-peptide-2 (GLP-2) analogues
CN104662038B (zh) 2012-07-23 2018-11-06 西兰制药公司 胰高血糖素类似物
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
KR102569036B1 (ko) 2013-10-17 2023-08-23 질랜드 파마 에이/에스 아실화된 글루카곤 유사체
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
CN105849122B (zh) 2013-11-06 2021-04-30 西兰制药公司 Gip-glp-1双重激动剂化合物及方法
US10131702B2 (en) 2013-11-06 2018-11-20 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
RU2716985C2 (ru) 2014-10-29 2020-03-17 Зилэнд Фарма А/С Соединения-агонисты gip и способы
RU2735762C2 (ru) 2015-04-16 2020-11-06 Зилэнд Фарма А/С Ацилированный аналог глюкагона, его применение и способы получения
EP3878462A1 (de) 2015-10-29 2021-09-15 CLS Therapeutics Limited Verwendung von dnase zur verbesserung der wirksamkeit und sicherheitsprofil der strahlentherapie gegen krebs.
US11179444B2 (en) 2016-06-09 2021-11-23 Amidebio, Llc Glucagon analogs and methods of use thereof
AU2017371516C1 (en) 2016-12-09 2021-09-02 Zealand Pharma A/S Acylated GLP-1/GLP-2 dual agonists
EP3638291B1 (de) * 2017-06-16 2021-08-18 Zealand Pharma A/S Dosierungsschemata zur verabreichung von glucagon-like-peptid-2 (glp-2)-analoga
WO2020020904A1 (en) 2018-07-23 2020-01-30 Zealand Pharma A/S Therapeutic uses of glp-2 agonists
EP3628683A1 (de) * 2018-09-28 2020-04-01 Zealand Pharma A/S Formulierungen von analoga des glucagon-like-peptid-2 (glp-2)
US20200254065A1 (en) 2019-02-11 2020-08-13 Opko Biologics Ltd. Long-acting glp-2 analogs
BR112022006546A2 (pt) 2019-10-07 2022-08-30 Kallyope Inc Agonistas de gpr119
BR112022023359A2 (pt) 2020-05-19 2023-04-18 Kallyope Inc Ativadores de ampk
EP4172162A1 (de) 2020-06-26 2023-05-03 Kallyope, Inc. Ampk-aktivatoren

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2961045B2 (ja) 1993-02-24 1999-10-12 日清製粉株式会社 腸管粘膜増強促進剤
US6184208B1 (en) 1994-06-29 2001-02-06 Immunotech Developments Inc. Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
US5990077A (en) 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5789379A (en) * 1995-04-14 1998-08-04 Allelix Biopharmaceutical Inc. Glucagon-like peptide-2 analogs
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
DK1975177T3 (da) 1996-03-01 2011-07-25 Novo Nordisk As Appetitundertrykkende peptid, formuleringer dermed og anvendelse deraf
US5912229A (en) 1996-03-01 1999-06-15 Novo Nordisk Als Use of a pharmaceutical composition comprising an appetite-suppressing peptide
CA2251576C (en) * 1996-04-12 2012-08-21 1149336 Ontario Inc. Glucagon-like peptide-2 analogs
SE9601438D0 (sv) * 1996-04-16 1996-04-16 Tetra Laval Holdings & Finance Plattvärmeväxlare
US5994500A (en) 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides
US20020025933A1 (en) 1996-08-30 2002-02-28 Knudsen Liselotte Bjerre GLP-2 derivatives
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
US5952301A (en) 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
CA2236519C (en) 1997-05-02 2011-09-13 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
US6051557A (en) 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
MXPA99010523A (es) * 1997-05-16 2004-09-01 Ontario Inc 1149336 Metodos para mejorar el funcionamiento del tractogastrointestinal superior.
US6803357B1 (en) 1998-02-02 2004-10-12 New England Medical Center Hospitals, Inc. Method of regulating glucose metabolism, and reagents related thereto
WO1999046283A1 (en) 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
WO1999058144A1 (en) 1998-05-11 1999-11-18 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
EP1076066A1 (de) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptide zur Senkung des Blutglukosespiegels
WO2001041779A2 (en) 1999-12-08 2001-06-14 1149336 Ontario Inc. Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment
JP5161412B2 (ja) 2000-09-18 2013-03-13 サノス・バイオサイエンス・アクティーゼルスカブ Ｇｌｐ−１及びｇｌｐ−２ペプチドの使用方法
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
WO2002066062A2 (en) 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity
AU2002233089B2 (en) 2001-02-16 2005-12-22 Conjuchem Biotechnologies Inc. Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
AU2002308706A1 (en) 2001-06-01 2002-12-16 Eli Lilly And Company Glp-1 formulations with protracted time action
WO2004035624A2 (en) 2002-10-14 2004-04-29 Novo Nordisk A/S Glucagon - like peptide - 2 variants
JP2006517389A (ja) * 2002-10-14 2006-07-27 ノボ　ノルディスク　アクティーゼルスカブ Ｇｌｐ−２化合物、製剤、及びそれらの使用
JP2007525425A (ja) * 2003-03-24 2007-09-06 ノボ　ノルディスク　アクティーゼルスカブ Ｇｌｐ−２誘導体
TW200526254A (en) 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
WO2005082404A2 (en) 2004-02-27 2005-09-09 Novo Nordisk A/S Glp-2 derivatives modified by lipophilic substituents
EP1809318B1 (de) 2004-11-01 2013-06-12 NPS Pharmaceuticals, Inc. Behandlung von patienten mit kurzdarmsyndrom und dickdarmkontinuität
KR101200227B1 (ko) 2005-05-04 2012-11-13 질랜드 파마 에이/에스 글루카곤 유사 펩티드-2(ｇｌｐ-2) 유사체
JP5819586B2 (ja) 2006-11-08 2015-11-24 ジーランド ファーマ アクティーゼルスカブ 選択的グルカゴン様ペプチド−２（ｇｌｐ−２）類似体
MX2011006313A (es) 2008-12-15 2011-09-27 Zealand Pharma As Analogos de glucagon.
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
JP6284471B2 (ja) 2011-05-18 2018-02-28 メデリス ダイアビーティーズ，エルエルシー インスリン抵抗性のための改善されたペプチドの調合薬
AU2013255752B2 (en) 2012-05-03 2017-11-09 Zealand Pharma A/S Glucagon-like-peptide-2 (GLP-2) analogues

Also Published As

Publication number Publication date
BRPI0718566A2 (pt) 2014-03-11
KR20090089308A (ko) 2009-08-21
EA023886B1 (ru) 2016-07-29
EP2051995B1 (de) 2017-02-08
IL198127A0 (en) 2011-08-01
UA102506C2 (ru) 2013-07-25
US10092648B2 (en) 2018-10-09
AU2007319066A1 (en) 2008-05-15
CA2669806C (en) 2018-10-02
MX2009004701A (es) 2009-05-21
CA2669806A1 (en) 2008-05-15
KR101527233B1 (ko) 2015-06-08
CN101573376B (zh) 2013-11-06
JP2010509197A (ja) 2010-03-25
US8642727B2 (en) 2014-02-04
AU2007319066B2 (en) 2013-09-19
US20120004392A1 (en) 2012-01-05
IL198127A (en) 2015-06-30
EA200900667A1 (ru) 2010-06-30
WO2008056155A1 (en) 2008-05-15
JP5819586B2 (ja) 2015-11-24
CN101573376A (zh) 2009-11-04
NZ576260A (en) 2012-04-27
US20140154214A1 (en) 2014-06-05
EP2051995A1 (de) 2009-04-29
NZ597554A (en) 2014-04-30

Similar Documents

Publication Publication Date Title
HK1136310A1 (en) Selective glucagon-like-peptide-2 (glp-2) analogues
IL195730A0 (en) New pyridine analogues
PL2001468T3 (pl) Analogi tiazolidynodionu
HK1126834A1 (en) Structural connectors
EP1841430A4 (de) Substituierte pyridazinyl- und pyrimidinyl-chinolin-4-ylamin-analoga
IL195980A0 (en) New pyridine analogues
PL2001469T3 (pl) Analogi tiazolidynodionu
ZA200810644B (en) New pyridine analogues
ZA200810647B (en) New pyridine analogues
IL188293A0 (en) New pyridine analogues
PL1854805T3 (pl) Pochodzące z kawy surfaktanty
EP2062892A4 (de) Mittel gegen hypertonie
GB0613952D0 (en) Antiviral agent
EP2030629A4 (de) Mittel zur verbesserung des lipid-stoffwechsels
GB2443290B (en) Separation agent
IL195982A0 (en) New pyridine analogues
EP2060263A4 (de) Mittel zur verbesserung des fettstoffwechsels
HK1113463A1 (en) Immunopotentiating agent
ZA200800157B (en) New pyridine analogues
TWM300304U (en) Light-increasing-diffusing structure
GB0617866D0 (en) Jarjar (jaropener)
ZA200810645B (en) New pyridine analogues
ZA200810422B (en) New pyridine analogues
GB0711673D0 (en) Glucagon analogues
GB0621782D0 (en) Antiviral agent

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20191108